DARA BioSciences, Inc.
http://www.darabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DARA BioSciences, Inc.
Midatech Survival Plan Scuppered By Shareholders
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Midatech Bets on Bioasis Merger For Survival
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
Elypta Drops Data Showing Power Of Metabolite-Based MCED Test
Elypta’s MIRAM kit for multi-cancer early detection performed well in a large-scale study.
Shionogi Reveals Strategy For COVID-19 Drug Xocova
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
Company Information
- Other Names / Subsidiaries
-
- Oncogenerix, Inc.
- Point Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice